Pharmacist Payor Enrollment for Optimized Reimbursement: Experience at Oregon Health & Science University

PURPOSE: An assessment of financial implications of pharmacist provider enrollment and factors influencing reimbursement for pharmacist clinic services within an academic medical center in Portland, Oregon are described. SUMMARY: This is an IRB exempt descriptive, retrospective, financial and policy analysis of pharmacist billing practices within adult and pediatric ambulatory specialty clinics. We examined pathways for pharmacist provider enrollment with different billing structures and payors from calendar year 2024 at Oregon Health & Science University (OHSU). Overall, findings validated payor enrollment, identified potential financial benefits, and outlined operational considerations to inform the expansion of pharmacist billing models.Reimbursement rates and monetary value of pharmacist clinical services were compared among three billing frameworks: hospital-based outpatient clinics, physician-based outpatient clinics, and one enrolled pharmacist practicing within a physician-based clinic. Successful reimbursement occurred in 48% of claims from hospital-based clinics, 88% of claims from physician-based clinics, and 95% of claims submitted by the enrolled pharmacist. The enrolled pharmacist achieved a higher average reimbursement value per claim than unenrolled pharmacists in a similar setting. CONCLUSION: At OHSU, pharmacist provider enrollment may improve reimbursement rates and reimbursement value within physician-based outpatient clinics, particularly when payor mixes include Oregon Medicaid and other payors that recognize pharmacist services. Despite potential benefits, reimbursement opportunities through pharmacist provider enrollments are likely limited in predominantly government-sponsored, hospital-based clinic settings. Organizations considering pharmacist provider enrollment should evaluate state reimbursement laws, institutional billing infrastructure, and clinic-specific payor mix to determine financial feasibility.